Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC
Yi‐Long Wu(Guangdong Academy of Medical Sciences), Thomas John(Austin Health), Christian Grohé(Evangelische Lungenklinik Berlin), Margarita Majem(Hospital de Sant Pau), Jonathan W. Goldman(University of California, Los Angeles), Sang‐We Kim(Ulsan College), Terufumi Kato(Kanagawa Prefectural Hospital Organization), К. К. Лактионов(Ministry of Health of the Russian Federation), Hữu Vĩnh Vũ(Cho Ray Hospital), Zhijie Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Shun Lü(Shanghai Jiao Tong University), Kye Young Lee(Konkuk University Medical Center), Charuwan Akewanlop(Siriraj Hospital), Chong‐Jen Yu(National Taiwan University Hospital), Filippo de Marinis(European Institute of Oncology), Laura Bonanno(Istituto Oncologico Veneto), Manuel Dómine(Hospital Universitario Fundación Jiménez Díaz), Frances A. Shepherd(University Health Network), Lingmin Zeng(AstraZeneca (United States)), Ajlan Atasoy(AstraZeneca (United Kingdom)), Roy S. Herbst(Yale Cancer Center), Masahiro Tsuboi(National Cancer Center Hospital East)
Cited by 151Open Access
Abstract
Related Papers
Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer
Jean‐Charles Soria, Yuichiro Ohe, Johan Vansteenkiste et al.|New England Journal of Medicine|2017|5.2k
Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group
Jean‐Pierre Pignon, Hélène Tribodet, Giorgio V. Scagliotti et al.|Journal of Clinical Oncology|2008|2.7k